Drug-drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers.
Fujita H, Arai S, Arakawa H, Hamamoto K, Kato T, Arai T, Nitta N, Hotta K, Hosokawa N, Ohbayashi T, Takahashi C, Inokuma Y, Tamai I, Yano S, Kunishima M, Watanabe Y.
Fujita H, et al.
Bioorg Med Chem. 2024 Mar 15;102:117674. doi: 10.1016/j.bmc.2024.117674. Epub 2024 Mar 2.
Bioorg Med Chem. 2024.
PMID: 38457912